Section one: Contracting authority/entity
one.1) Name and addresses
Department of Health and Social Care
39 Victoria Street
London
SW1H 0EU
Country
United Kingdom
NUTS code
UKI32 - Westminster
Internet address(es)
Main address
https://www.gov.uk/government/organisations/department-of-health-and-social-care
Buyer's address
https://www.gov.uk/government/organisations/department-of-health-and-social-care
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Contract for the supply of live attenuated intranasal influenza vaccine
Reference number
CM/PHV/14/5433
two.1.2) Main CPV code
- 33651660 - Influenza vaccines
two.1.3) Type of contract
Supplies
two.2) Description
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
Main site or place of performance
Bedford, UK
two.2.4) Description of the procurement at the time of conclusion of the contract:
The provision of a live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme, which includes children. The volume requirement is 3,364,470 doses of vaccine.
two.2.7) Duration of the contract, framework agreement, dynamic purchasing system or concession
Start date
1 August 2018
End date
31 July 2022
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.2) Administrative information
four.2.1) Contract award notice concerning this contract
Notice number: 2021/S 000-016455
Section five. Award of contract/concession
Contract No
CM/PHV/14/5433
five.2) Award of contract/concession
five.2.1) Date of conclusion of the contract/concession award decision:
9 February 2018
five.2.2) Information about tenders
The contract/concession has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor/concessionaire
AstraZeneca
1 Francis Crick Avenue
Cambridge
LCB2 0AA
Country
United Kingdom
NUTS code
- UKH1 - East Anglia
National registration number
03674842
Internet address
The contractor/concessionaire is an SME
No
five.2.4) Information on value of the contract/lot/concession (at the time of conclusion of the contract;excluding VAT)
Total value of the procurement: £1
Section six. Complementary information
six.3) Additional information
Value — this information is considered by the supplier to be commercially sensitive information. The authority is not publishing the value so as not to prejudice the legitimate commercial interest of the supplier.
six.4) Procedures for review
six.4.1) Review body
The High Court
Strand
London
WC2A 2LL
generaloffice@administrativecourtoffice.justice.gov.uk
Country
United Kingdom
Internet address
Section seven: Modifications to the contract/concession
seven.1) Description of the procurement after the modifications
seven.1.1) Main CPV code
- 33651660 - Influenza vaccines
seven.1.3) Place of performance
NUTS code
- UK - United Kingdom
Main site or place of performance
Bedford, UK
seven.1.4) Description of the procurement:
The provision of additional doses of live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme in the UK. The additional volume requirement is 37,160 doses of vaccine.
seven.1.5) Duration of the contract, framework agreement, dynamic purchasing system or concession
Start date
1 August 2018
End date
31 July 2022
seven.1.6) Information on value of the contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession:
£1
seven.1.7) Name and address of the contractor/concessionaire
AstraZeneca
1 Francis Crick Avenue
Cambridge
LCB2 0AA
Country
United Kingdom
NUTS code
- UKH1 - East Anglia
National registration number
03674842
Internet address
The contractor/concessionaire is an SME
No
seven.2) Information about modifications
seven.2.1) Description of the modifications
Nature and extent of the modifications (with indication of possible earlier changes to the contract):
The provision of additional doses of live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme in the UK. The additional volume requirement is 37,160 doses of vaccine.
seven.2.2) Reasons for modification
Need for additional works, services or supplies by the original contractor/concessionaire.
Description of the economic or technical reasons and the inconvenience or duplication of cost preventing a change of contractor:
The additional doses of LAIV are necessary for the Government’s children’s flu programme; AstraZeneca have exclusive rights to manufacture and supply a LAIV product (Fluenz Tetra) and are the only supplier in the UK of a LAIV product with marketing authorisation which means DHSC cannot engage another supplier to provide the additional doses without significant inconvenience
seven.2.3) Increase in price
Updated total contract value before the modifications (taking into account possible earlier contract modifications, price adaptions and average inflation)
Value excluding VAT: £1
Total contract value after the modifications
Value excluding VAT: £1